P70S6K 1 regulation of angiogenesis through VEGF and HIF-1α expression

被引:73
作者
Bian, Chuan-Xiu [2 ]
Shi, Zhumei [2 ]
Meng, Qiao [1 ]
Jiang, Yue [1 ]
Liu, Ling-Zhi [1 ]
Jiang, Bing-Hua [1 ,2 ]
机构
[1] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA
[2] Nanjing Med Univ, Ctr Canc, Dept Pathol, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
p70S6K1; VEGF; HIF-1; Tumor angiogenesis; siRNA; ENDOTHELIAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL; 3-KINASE; MAMMALIAN TARGET; OVARIAN-CANCER; SIGNALING PATHWAY; KINASE-ACTIVITY; MTOR; RAPAMYCIN; CELLS; TRANSLATION;
D O I
10.1016/j.bbrc.2010.06.080
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 70 kDa ribosomal S6 kinase 1 (p70S6K1), a downstream target of phosphoinositide 3-kinase (PI3K) and ERK mitogen-activated protein kinase (MAPK), is an important regulator of cell cycle progression, and cell proliferation. Recent studies indicated an important role of p70S6K1 in PTEN-negative and AKT-overexpressing tumors. However, the mechanism of p70S6K1 in tumor angiogenesis remains to be elucidated. In this study, we specifically inhibited p70S6K1 activity in ovarian cancer cells using vector-based small interfering RNA (siRNA) against p70S6K1. We found that knockdown of p70S6K1 significantly decreased VEGF protein expression and VEGF transcriptional activation through the HIF-1 alpha binding site at its enhancer region. The expression of p70S6K1 siRNA specifically inhibited but HIF-1 alpha, but not HIF-1 beta protein expression. We also found that p70S6K1 down-regulation inhibited ovarian tumor growth and angiogenesis, and decreased cell proliferation and levels of VEGF and HIF-1 alpha expression in tumor tissues. Our results suggest that p70S6K1 is required for tumor growth and angiogenesis through HIF-1 alpha and VEGF expression, providing a molecular mechanism of human ovarian cancer mediated by p70S6K1 signaling. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:395 / 399
页数:5
相关论文
共 34 条
  • [1] AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
    Altomare, DA
    Wang, HQ
    Skele, KL
    De Rienzo, A
    Klein-Szanto, AJ
    Godwin, AK
    Testa, JR
    [J]. ONCOGENE, 2004, 23 (34) : 5853 - 5857
  • [2] A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
    Aoki, M
    Blazek, E
    Vogt, PK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) : 136 - 141
  • [3] Burroughs KD, 2003, MOL CANCER RES, V1, P312
  • [4] Byrne AT, 2003, CLIN CANCER RES, V9, P5721
  • [5] Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival
    Chen, CA
    Cheng, WF
    Lee, CN
    Chen, TM
    Kung, CCS
    Hsieh, FJ
    Hsieh, CY
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 74 (02) : 235 - 240
  • [6] PDGF-DEPENDENT AND INSULIN-DEPENDENT PP70(S6K) ACTIVATION MEDIATED BY PHOSPHATIDYLINOSITOL-3-OH KINASE
    CHUNG, JK
    GRAMMER, TC
    LEMON, KP
    KAZLAUSKAS, A
    BLENIS, J
    [J]. NATURE, 1994, 370 (6484) : 71 - 75
  • [7] Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer
    Diniz Bizzo, Solange Maria
    Meira, Debora Dummer
    Lima, Jose Marinaldo
    Mororo, Janio da Silva
    Casali-da-Rocha, Jose Claudio
    Faria Ornellas, Maria Helena
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2010, 109 (02) : 113 - 117
  • [8] Mechanism of action of the immunosuppressant rapamycin
    Dumont, FJ
    Su, QX
    [J]. LIFE SCIENCES, 1995, 58 (05) : 373 - 395
  • [9] Integrinαvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis
    Eliceiri, BP
    Klemke, R
    Strömblad, S
    Cheresh, DA
    [J]. JOURNAL OF CELL BIOLOGY, 1998, 140 (05) : 1255 - 1263
  • [10] Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
    Fingar, DC
    Blenis, J
    [J]. ONCOGENE, 2004, 23 (18) : 3151 - 3171